NewcelX Ltd.
NCEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.28M
Close$
$0.48
81.6% downside
Current Fair Value
81.6% downsideOvervalued by 81.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.28 Million |
|---|---|
| Enterprise Value | $14.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.16 |
| Beta | 0.93 |
| Outstanding Shares | 5,856,314 |
Return
| Return on Equity | -11.92% |
|---|---|
| Return on Assets | -7.42% |
| Return on Invested Capital | -126.77% |
Valuation & Multiples
| P/E Ratio | 9.23 |
|---|---|
| PEG | 30.16 |
| Price to Sales | - |
| Price to Book Ratio | 2.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.95 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.65
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About NLS Pharmaceutics Ltd
4 employees
CEO: Ronen Twito NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system d...